Next Article in Journal
Repetitive Low-Intensity Vestibular Noise Stimulation Partly Reverses Behavioral and Brain Activity Changes following Bilateral Vestibular Loss in Rats
Previous Article in Journal
Total 25-Hydroxyvitamin D Is an Independent Marker of Left Ventricular Ejection Fraction in Heart Failure with Reduced and Mildly Reduced Ejection Fraction
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomolecules
Volume 13
Issue 11
10.3390/biom13111576
biomolecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Efficacy of Sub-Gingivally Delivered Propolis Nanoparticle in Non-Surgical Management of Periodontal Pocket: A Randomized Clinical Trial

by
Sushree Ambika Sahu
1,
Saurav Panda
1,*,
Abhaya Chandra Das
1,
Lora Mishra
2,
Satchidananda Rath
3,
Krzysztof Sokolowski
4,
Manoj Kumar
1,
Rinkee Mohanty
1,
Rashmita Nayak
1,
Anurag Satpathy
1 and
Barbara Lapinska
5,*
1
Department of Periodontics and Oral Implantology, Institute of Dental Sciences, Siksha ‘O’ Anusandhan University, Bhubaneswar 751003, Odisha, India
2
Department of Conservative Dentistry & Endodontics, Institute of Dental Sciences, Siksha ‘O’ Anusandhan University, Bhubaneswar 751003, Odisha, India
3
Department of Physics, School of Basic Sciences, Indian Institute of Technology, Bhubaneswar 752050, Odisha, India
4
Department of Conservative Dentistry, Medical University of Lodz, 251 Pomorska St., 92-213 Lodz, Poland
5
Department of General Dentistry, Medical University of Lodz, 251 Pomorska St., 92-213 Lodz, Poland
*
Authors to whom correspondence should be addressed.
Biomolecules 2023, 13(11), 1576; https://doi.org/10.3390/biom13111576
Submission received: 8 September 2023 / Revised: 18 October 2023 / Accepted: 24 October 2023 / Published: 26 October 2023
(This article belongs to the Section Natural and Bio-inspired Molecules)
Browse Figures
Versions Notes

Abstract

:
Naturally sourced products like propolis are commonly employed for the non-surgical treatment of periodontal pockets. The use of nanoparticle formulations of these natural remedies has the potential to improve treatment outcomes. The aim of the present study was to evaluate the efficacy of sub-gingivally delivered propolis nanoparticles in the non-surgical management of periodontal pockets. Forty patients diagnosed with periodontitis presenting at least one periodontal pocket with a probing pocket depth between 4 and 6 mm were selected. Patients were randomly assigned into the control group (n = 20), which received scaling and root planing (SRP) and saline (SRP + Saline), and the test group (n = 20), which received SRP and sub-gingivally delivered propolis nanoparticles (PRO) into the periodontal pocket (SRP + PRO). The clinical parameters recorded were plaque index (PI), gingival index (GI), relative attachment loss (RAL), probing pocket depth (PPD), and bleeding on probing (BOP). They were assessed at baseline, one month, and three months post therapy. The results indicated that there was a significant improvement in clinical parameters (p < 0.05) in the test sites compared with the control sites at the end of the study. The gingival index at one month and three months was found to be significantly better in the SRP + PRO group than the SRP + Saline group, with a p value of <0.001. The BOP, PPD, and RAL showed significant improvement with the SRP + PRO group at the end of the 3-month follow-up with p values of 0.0001, 0.001, and 0.05, respectively. The subgingival delivery of propolis nanoparticles showed promising results as an adjunct to SRP in patients with periodontitis presenting periodontal pockets.

1. Introduction

Periodontal disease [PD] is an immuno-inflammatory destructive disease of periodontal tissues characterized by the loss of soft tissue attachment and alveolar bone loss caused by pathogenic microorganisms resulting in pocket formation and/or gingival recession [1]. Periodontal disease is one of the most common chronic infectious diseases among adults and is caused by the accumulation of bacterial biofilm [1,2].
The periodontal pocket is a pathologically deepened gingival sulcus caused by the apical migration of junctional epithelium. The coronal movement of the gingival margin without the destruction of underlying periodontal tissues creates a pseudo pocket or gingival pocket, whereas the apical migration of the junctional epithelium with the destruction of supporting periodontal tissues is responsible for developing a true pocket or periodontal pocket [3].
Non-surgical periodontal therapy is considered as a “golden standard” treatment protocol for periodontal pockets because it involves scaling and root planing (SRP) to remove supra and subgingival biofilms, plaque, and calculus from diseased root surfaces [4,5]. It is proven that the non-surgical approach is an effective treatment strategy with periodontal pockets measuring less than the critical probing depth of 2.9 mm. However, in cases of deep periodontal pockets, surgical periodontal therapy along with periodontal regeneration stands to be a viable option, as complete debridement of biofilm remains crucial due to the presence of extensive periodontal tissue destruction.
Periodontal regeneration involves the use of various biomaterials like autogenous bone grafts [6], demineralized freeze-dried bone graft [7], xenografts [8,9], barrier membranes and different types of bone grafts [10], enamel matrix derivatives [11], platelet-rich fibrins [12,13], calcium sulphate [14], chitosan [15], and three-dimensional hydrogels (collagen, chitosan, hyaluronic acid-based) [16] combined with surgical procedures. Autologous platelet concentrates are effective, along with other regenerative materials, or alone in the treatment of intra-bony defects, furcation defects, and alveolar sockets [17,18]. Recent periodontal regenerative therapies using leukocyte- platelet-rich fibrin added to autogenous bone grafts [19] or inorganic bovine [9] showed favorable effects in hard and soft tissue regeneration.
Periodontal pockets present an ideal site for treatment using localized drug delivery systems. Within the field of periodontics, there are established approaches for delivering drugs directly to subgingival sites or periodontal pockets. These systems release antimicrobial agents either instantly or in a controlled and sustained manner, effectively countering microbial threats while minimizing potential adverse effects on non-oral parts of the body. Currently, a range of local drug delivery systems are available, including fibers, gels, strips, films, irrigating systems, and microparticles [20,21,22].
Propolis is a natural, non-toxic, resinous, yellow–brown to dark brown substance collected through honey bees from trees, buds, sap flow, shrubs, and other plant sources [23,24]. Propolis has various beneficial properties like antimicrobial, anticancer, antifungal, antiviral, and anti-inflammatory effects [25,26,27]. Propolis has been used extensively for the treatment of periodontitis in various forms such as paste, tablet, ointment, oil, mouthwash, etc. [28,29,30,31,32,33,34,35,36,37,38], or in patients undergoing oral surgical procedures where oral hygiene might have been impaired [39,40,41]. Propolis has also been used sub-gingivally for the management of periodontal pocket in patients with periodontitis [42,43] and has been found to be very effective.
This study aimed and was designed to explore the direct subgingival delivery of propolis nanoparticles into the periodontal pocket, serving as a local drug delivery (LDD) agent for the non-surgical management of periodontal pockets.

2. Materials and Methods

The present study was a prospective, double-blind, randomized clinical trial of parallel design (one site/patient) conducted among patients that visited the outpatient Department of Periodontics and Oral Implantology, Institute of Dental Sciences, SUM hospital, Siksha ‘O’Anusandhan (Deemed to be University), Bhubaneswar, Odisha. The ethical committee of IMS and SUM Hospital, SOA (Deemed to be University) approved the study with Ethical Number: Ref. no/IEC/IMS.SH/SOA/2022/418. This study strictly followed the CONSORT guidelines and was in accordance with the Declaration of Helsinki.
Patients were recruited based on the following inclusion and exclusion criteria.
Systemically healthy patients within the age group of 18–65 years, showing an acceptable oral hygiene with plaque scores of less than 1.5, who were diagnosed with generalized periodontitis of stages II and III (According to World Workshop of Periodontology, 2017 [44,45]) with at least one periodontal pocket with probing pocket depth of between 4 and 6 mm were included in the study. Smokers; pregnant and lactating mothers; patients who are allergic to propolis products; patients who received radiotherapy, chemotherapy or immunosuppressive treatments, systemic corticosteroids, and/or anticoagulants 30 days prior to intervention; patients with any systemic disease; and patients under the influence of non-steroidal anti-inflammatory drugs (NSAIDS) or any other anti-inflammatory medications, antibiotics, steroids that can alter the course of periodontitis progression and treatment were excluded.

2.1. Preparation Protocol of Propolis Nanoparticle as Liquid Solution and Application

Indian honey bee propolis was collected from Bhubaneswar, Odisha in November 2021. It then went through a cold-water washing process to remove the wax. The remaining part was dried, ground, and stored at 8 °C for further use. Propolis nanoparticle solution was prepared at room temperature by dissolving 0.22 g ground and dried propolis in 20 mL Milli-Q water, i.e., equivalent to 1.08 wt.%, using a 0.5-inch probe sonicator (Q500 Sonicator®, Qsonica, Newtown, CT, USA) for 4 h at room temperature, 300 K. The probe tip size used was 1 cm and the sonication depth was approximately 2 cm. The amplitude and intensity of sonication were set at 50% and 40 W, respectively. Then, the solution was filtered using Whatman 40 filter paper and extract was part stored at 8 °C for further applications. The propolis nanoparticle solution was sub-gingivally delivered inside the periodontal pocket and pocket was sealed using cyano-acrylate.
The size distribution of the propolis nanoparticles was determined using dynamic light scattering (DLS) analysis (Zeta-sizer Ultra, Malvern Panalytical, Malvern, UK). This technique measures the intensity-based size distribution of particles in a suspension. The results revealed a mean particle size with a range of 88.6 to 103 nanometers in diameter, with the largest particle size of 140 nm in diameter. The zeta potential of the propolis nanoparticles was assessed using zeta potential analysis (Zeta-sizer Ultra, Malvern Panalytical, Malvern, UK). This technique measures the electrostatic charge present on the surface of the particles. The results demonstrated a zeta potential of −20.51 mV, indicating the stability of the nanoparticles.
The morphology of the propolis nanoparticles was examined through field emission scanning electron microscopy (FE-SEM) (Merlin Compact, Carl Zeiss, Jena, Germany). Micrographs obtained from FE-SEM analysis showed flower-shaped nanoparticles with a relatively uniform size distribution with sizes ranging between 88.6 and 103 nm with a structural diameter of less than 100 nm (Figure 1).

2.2. Biocompatibility of Propolis Nanoparticle

The biocompatibility of the obtained nanoparticle was carried out using MTT assay. The details can be found in Appendix A (Figure A1).

2.3. Study Groups

The selected sites of all patients were marked and assigned randomly either to the control group or test group.
Test Group (SRP + PRO) (n = 20): sites treated with SRP followed by sub-gingival delivery of propolis nanoparticle.
Control Group (SRP + Saline) (n = 20): sites treated with SRP followed by sub-gingival delivery of saline (placebo).

2.3.1. Randomization and Blinding

The randomization was carried out using computer generated table of random numbers. The allocated groups were concealed using opaque sealed envelopes, which were opened prior to the sub-gingival delivery of LDD propolis nanoparticle or saline. The study was double-blind, where both the participants and investigator were unaware of the substance delivered.

2.3.2. Patient Examination

On their first visit, all patients were clinically examined and the following indices were recorded: plaque index (PI) (site specific plaque index by Löe and Silness in 1967 [46]), gingival index (GI) (Löe and Silness, 1963 [47]), sulcus bleeding index (BI) (Muhlemann and Son, 1971 [48]), probing pocket depth (PPD), and relative attachment level (CAL). These indices or outcomes were measured at all six surfaces of the selected tooth (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual). These parameters were recorded at one month and three months after therapy.

2.3.3. Technique for Sub-Gingival Delivery of Propolis

After baseline examination, test sites were treated with SRP followed by subgingival administration of propolis nanoparticle in the liquid solution form through blunt cannula, and control sites were treated with SRP followed by subgingival administration of saline as a placebo through a blunt cannula. The pockets were sealed using isoamyl-2-cyanoacrylate (Amcrylate). Clinical parameters were assessed at one month and three months after therapy.

2.4. Statistical Analysis

A sample size of 40 subjects and 20 subjects in each group were estimated to achieve 80% power in a two-tailed comparative test between the groups (p ≤ 0.05) by considering the mean difference of RAL 1.0 mm to be statistically significant between the test and control groups. The collected data were analyzed by using Statistical Package for Social Sciences (SPSS) software version 17.0. The data were tested for normality using Kolmogorov–Smirnov test and Shapiro–Wilk test. Mann–Whitney U test was employed to compare the data between two groups for inter-group comparison. Value of p ≤ 0.05 was considered to be statistically significant and p < 0.001 was considered highly statistically significant.

3. Results

A total of 52 subjects were screened for this study. Out of fifty-two subjects, eight did not meet the inclusion criteria and four refused to participate in this randomized controlled clinical trial. Therefore, 40 patients (10 females, 30 males) finally participated in this study. The patients were in the age group 18–65 years with probing pocket depths between 4 and 6 mm (Generalized periodontitis patients of stage II and III according to AAP classification, 2017 [45]). All the participants completed the study and there were no dropouts (Figure 2).
The data collected was subjected to statistical analysis using SPSS software, version 17.0. The p-value was set as 0.05 to represent statistical significance. The distribution of treated tooth of each subject and demographic details between two groups are provided in Table 1 and Table 2.
No significant differences between the groups were observed for plaque index at 1-month and 3-month time interval with p value equal to 0.429. The gingival index at 1 month and 3 months was found to be significantly better in SRP + PRO group than the SRP + Saline group with p value of <0.001 (Table 3).
The BOP, PPD, and RAL showed significant improvement with the SRP + PRO group at the end of 3 months follow-up with p values of 0.0001, 0.001, and 0.05, respectively (Table 4).
The change in all clinical parameters like GI, BOP, PPD, and RAL was found to be significantly better with the SRP + PRO group compared with the SRP + Saline group, except for PI with p value of 0.253 at the end of 1 month. However, change in PI at the end of 3 months was shown to be significantly better with the SRP + PRO group (Table 5).

4. Discussion

Propolis is a natural resinous substance collected by honeybees from tree buds, sap flows, and other botanical sources [49,50]. It has been used for its medicinal properties for thousands of years, and recent studies have shown that propolis contains various bioactive compounds, including flavonoids, phenolic acids, terpenes, and esters. Propolis has been found to have antibacterial, antifungal, antiviral, anti-inflammatory, and antioxidant properties, making it a promising agent for the treatment of periodontal pockets [51,52,53,54,55,56,57].
Propolis has also been used as a promising agent in the treatment of periodontal disease, like the use of PRF in regenerative dentistry, and shows promising results in soft tissue as well as hard tissue healing [13,17,18,58,59,60,61,62,63,64,65]. Probiotics also play an important role in the non-surgical management of periodontitis [66]. In this study, the use of propolis nanoparticles in the non-surgical treatment of periodontal pockets showed similar promising results.
However, several contributing factors may affect treatment outcome. Poor oral hygiene is detrimental and maintaining a good oral hygiene is essential for preventing various oral diseases, including gingivitis, periodontitis, and bad breath [67]. Another contributing factor is the use of certain medications. Some medications, such as antihistamines, antidepressants, and antihypertensive drugs, can cause dry mouth, which reduces saliva flow and increases the risk of oral health problems [68,69,70]. Similarly, individuals who use tobacco products or consume alcohol excessively may have a higher risk of developing oral diseases due to the detrimental effects of these substances on oral health [71,72]. Poor dietary habits can also affect oral hygiene. A diet high in sugar and processed foods can increase the risk of dental caries, while a diet lacking in essential nutrients, such as calcium and vitamin D, can lead to weakened teeth and gums [73,74,75,76,77,78,79,80,81]. Lastly, mental health and stress levels can also play a role in maintaining oral hygiene, which can cause damage to the teeth and gums over time [82,83,84,85,86,87,88].
Scaling and root planing is a non-surgical periodontal therapy that is commonly used to treat patients with periodontitis [89]. In this study, ultrasonic scaling and root planing was used to perform mechanical debridement in patients suffering from chronic periodontitis. Overall, both ultrasonic and manual methods of mechanical debridement are effective for subgingival instrumentation, and the choice between them may depend on factors such as the severity of the patient’s periodontitis and their level of discomfort [89].
In this study, the use of Indian propolis in the form of nanoparticles for the treatment of periodontal pockets showed promising results. Other studies have investigated the beneficial effects of propolis from different plant sources on periodontal treatment outcomes and the beneficial effects of propolis may be based on the source of origin related to the geographical area. Recently, propolis has been used in various formulations for the treatment of periodontitis because of some disadvantages of raw propolis, such as strong and unpleasant taste, strong aromatic smell, and high ethanol concentration [57,90]. So, the application of microparticles can improve and increase the therapeutic effect from biomedical materials or from drugs. However, the microparticles did not show activity against all the tested strains until the concentration of 0.30 mg/mL [91], but in other study, propolis showed in vitro antimicrobial activity against all the tested microorganism strains [92]. Recently, propolis nanoparticles (a size of less than 100 nanometers) have gained attention as a potential therapeutic agent for periodontitis due to their unique physicochemical properties, such as high surface area-to-volume ratio and increased bioavailability. This study suggests that propolis nanoparticles have potential as a natural and effective treatment option for periodontal pockets, but further research is needed to fully understand their mechanisms of action and optimize their formulation and delivery for clinical use.
Biocompatibility testing is essential in determining the safety and effectiveness of any dental material, including propolis, before its clinical use. It has been investigated in several studies on human gingival fibroblasts (HGF), dental pulp stem cells (DPSCs), and periodontal ligament (PDL) cells, which have suggested that propolis extracts may have potential for use in periodontal treatment [93,94,95]. In this study, the cell viability of propolis nanoparticles was tested using MTT assay for 24 h and >80% cell viability was present at 100% concentration in HGF, DPSCs, and PDL cells. Our study revealed that propolis nanoparticles exhibited a greater inhibition of DPSCs and HGF compared with PDL cells. It is important to note that our in vitro study evaluated the effects of propolis nanoparticles on isolated cell cultures, which may not fully replicate the complex microenvironment of the gum tissue in vivo.
In this study, the change in all the clinical parameters like GI, BOP, PPD, and RAL was found to be significantly better with the SRP + PRO group compared with the SRP + Saline group at end of the 1-month and 3-month time-interval. Similar results were obtained by previous studies which used other active agents like probiotics [96], chlorhexidine [97], PRGF [13], and tea-tree oil [98] as subgingival delivery or intra-pocket delivery agents for the management of periodontal pockets at a 3-month time interval.
Propolis has been used extensively for the treatment of periodontitis in various forms such as toothpaste [31,34,35] and mouthwash [29,32,35] due to its various beneficial properties like antimicrobial, anticancer, antifungal, antiviral, and anti-inflammatory effects [25,26,27]. Several studies have investigated the effectiveness of the subgingival irrigation of propolis for the treatment of periodontitis and found that propolis irrigation improves clinical parameters as well as significantly reduces the number of bacteria in periodontal pockets, particularly anaerobic bacteria that are associated with periodontitis. In the present study, a significant increase in PPD and RAL was observed at the 3-month recall check-up in both the groups but more gain was seen in test group sites along with improvements in other clinical and microbiological parameters, which shows the efficacy of propolis nanoparticles as local drug delivery in the form of a liquid solution over SRP alone.
In periodontics, various tissue adhesives have been investigated for the closure of periodontal pockets [99]. The use of fibrin and cyanoacrylate glue showed fast control over bleeding, easy to apply and beneficial in terms of patient’s acceptance, especially in periodontal surgeries [100,101,102]. In this study, isoamyl 2-cyanocrylatec (Bio-adhesive) was used to seal periodontal pockets after the placement of a propolis nanoparticle as a local drug delivery system for the sustained release of the entrapped drug into the periodontal pocket.
The current study is a randomized controlled trial, with a parallel design, comparing the use of the intra-pocket delivery of propolis nanoparticles. Split-mouth design is considered to be ethically sound as each patient receives both the experimental and control interventions [103]. A split-mouth study design to evaluate the efficacy of propolis nanoparticles may be a future concern.
The decision to exclude stage IV periodontitis patients from our study was based on several factors. Firstly, stage IV periodontitis is characterized by severe periodontal tissue destruction, including extensive bone loss and tooth mobility. These patients often require more complex and aggressive treatment approaches, such as surgical interventions and advanced periodontal therapies. Our study, on the other hand, focused on assessing the effectiveness of a specific non-surgical intervention in early to moderate stages of periodontitis.
Including stage IV patients would have introduced significant heterogeneity to the study population, with varying treatment needs and potential confounding factors that could impact the outcomes. It is important to note that the exclusion of these patients was not meant to undermine the significance of their condition, but rather to maintain a homogeneous study population with similar baseline characteristics and treatment requirements.
Propolis is generally considered safe and well-tolerated. However, propolis as a natural product may contain environmental pollutants including heavy metals [104]. There was no adverse effect seen in any of the patients treated with propolis in the present study. The various benefits of propolis such as affordability, easy availability, and antibacterial and anti-inflammatory properties, make propolis a potential therapeutic agent in periodontal therapy. The strength of this study lies in its rigorous study methodology of treating one site per patient to avoid the confounding bias of pocket recolonization and being the first study of its kind to evaluate the effects of propolis nanoparticles in the non-surgical management of periodontal pockets. The limitations of the present study include a small sample size, a shorter follow-up time limited to a maximum of 3 months, and a lack of biomarker test. Considering the confounding variables, such as the severity of periodontal disease at baseline, the patients’ oral hygiene practices, and their compliance with treatment protocols, could have impacted the response to the propolis nanoparticle intervention. Future research is warranted to consider these factors.

5. Conclusions

In conclusion, our study demonstrates the potential of propolis nanoparticles as a natural and effective treatment option for periodontal pockets. The sub-gingival administration of propolis nanoparticles with scaling and root planing resulted in significant improvements in various periodontal parameters, including reductions in GI, BOP, PPD, and RAL compared with the control sites treated with saline and SRP.
The subgingival delivery of propolis nanoparticles as an addition to scaling and root planing holds promise for the treatment of chronic periodontitis. Future investigations should explore the effects of higher concentrations of propolis extract and increased frequency of application, as they may potentially yield even more favorable outcomes. Moreover, additional research with larger sample sizes and longer observation periods is necessary to gain a comprehensive understanding of the mechanisms underlying propolis nanoparticles’ action, optimize their formulation and delivery, and establish their safety and efficacy in human subjects.
Overall, propolis nanoparticles exhibit encouraging potential as a natural therapeutic approach for managing periodontal pockets. Continued scientific inquiry and clinical trials will contribute to further refining this treatment modality and expanding its application in the field of periodontics.

Author Contributions

Conceptualization, S.A.S. and S.P.; methodology, S.P., S.A.S. and A.C.D.; software, A.S. and R.N.; validation, S.R., R.N., K.S. and S.P.; formal analysis, M.K.; investigation, S.A.S.; resources, S.P., K.S. and S.A.S.; data curation, M.K. and R.M.; writing—original draft preparation, S.P. and S.A.S.; writing—review and editing, R.M., R.N., A.C.D. and B.L.; visualization, A.S., L.M. and B.L.; supervision, L.M. and S.P.; project administration, S.P. and S.R. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki. The ethical committee of IMS and SUM Hospital, SOA (Deemed to be University) approved the study with Ethical Number: Ref. no/IEC/IMS.SH/SOA/2022/418.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Conflicts of Interest

The authors declare no conflict of interest.

Appendix A

The biocompatibility of the obtained nanoparticle was carried out using an MTT assay.
A1.
Isolation of primary cells, Cell Culture, and Caffeic acid phenethyl ester (CAPE) Treatment
Primary cells like human gingival fibroblasts (HGF), dental pulp stem cells (DPSCc), and periodontal ligaments (PDL) cells were isolated through mechanical digestion and cultured in Dulbecco’s Modified Eagle’s Medium supplemented with a nutrient mixture, which comprised F-12 Ham’s medium (Life Technologies, Grand Island, NY, USA), 10% fetal bovine serum (Hyclone Laboratories, Logan, UT, USA), 2 mM glutamine,100 U/mL penicillin, and 100 μg/mL streptomycin. All cell cultures were maintained at 37 °C in a humidified atmosphere of 5% CO2. For CAPE treatment, appropriate amounts of stock solution of CAPE were added into a culture medium to achieve the indicated concentrations and then incubated with cells for indicated time periods, whereas dimethyl sulfoxide solution without CAPE was used as a blank reagent.
A2.
Determination of Cell Viability (MTT Assay)
For the cell viability experiment, a microculture tetrazolium (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) colorimetric assay was performed to determine the cytotoxicity of CAPE. Primary cells were seeded in 24-well plates at a density of 5 × 104 cells/well and treated with CAPE at a concentration between 0 and 40 μM at 37 °C for 24 and 48 h. After the exposure period, the media were removed, and cells were washed with phosphate-buffered saline (PBS) and then incubated with 20 μL MTT (5 mg/mL) (Sigma chemical Co., St. Louis, MO, USA) for 4 h. After MTT Assay, the experiment was under observation. Then, quantitative and qualitative analyses were performed using spectrophotometric and phase contrast microscopy methods, respectively. The viable cell number per dish was directly proportional to the production of formazan, which can be measured spectrophotometrically at 563 nm following solubilization with isopropanol.
The biocompatibility of the propolis nanoparticle was found to be high with more than 80% cell viability with HGF, DPSCc, and PDL cells at all given drug concentrations of the prepared solution compared with saline as a control (Figure A1).
Biomolecules 13 01576 g0a1
Figure A1. The cell viability of control and experimental groups was tested by MTT assay for 24 h, respectively, and absorbance was taken at 570 nm. Data are shown as means ± SD (n = 3), p < 0.001.
Figure A1. The cell viability of control and experimental groups was tested by MTT assay for 24 h, respectively, and absorbance was taken at 570 nm. Data are shown as means ± SD (n = 3), p < 0.001.
Biomolecules 13 01576 g0a1

References

  1. Lisbona-González, M.J.; Muñoz-Soto, E.; Reyes-Botella, C.; Olmedo-Gaya, M.V.; Diaz-Castro, J.; Moreno-Fernandez, J. Study of the Antimicrobial Effect of an Ethanolic Extract of Propolis in Periodontal Disease. Appl. Sci. 2021, 11, 7463. [Google Scholar] [CrossRef]
  2. Richards, D. Review Finds That Severe Periodontitis Affects 11% of the World Population. Evid. Based Dent. 2014, 15, 70–71. [Google Scholar] [CrossRef] [PubMed]
  3. Bosshardt, D.D. The Periodontal Pocket: Pathogenesis, Histopathology and Consequences. Periodontology 2018, 76, 43–50. [Google Scholar] [CrossRef]
  4. Cobb, C.M. Non-Surgical Pocket Therapy: Mechanical. Ann. Periodontol. 1996, 1, 443–490. [Google Scholar] [CrossRef]
  5. Tariq, M.; Iqbal, Z.; Ali, J.; Baboota, S.; Talegaonkar, S.; Ahmad, Z.; Sahni, J.K. Treatment Modalities and Evaluation Models for Periodontitis. Int. J. Pharm. Investig. 2012, 2, 106–122. [Google Scholar] [CrossRef]
  6. Kataria, S.; Chandrashekar, K.T.; Mishra, R.; Tripathi, V. Autogenous Bone Graft for Management of Periodontal Defects. J. Int. Clin. Dent. Res. Organ. 2016, 8, 70. [Google Scholar] [CrossRef]
  7. Rosen, P.S.; Reynolds, M.A.; Bowers, G.M. The Treatment of Intrabony Defects with Bone Grafts. Periodontology 2000, 22, 88–103. [Google Scholar] [CrossRef]
  8. Hanna, R.; Trejo, P.M.; Weltman, R.L. Treatment of Intrabony Defects with Bovine-Derived Xenograft Alone and in Combination with Platelet-Rich Plasma: A Randomized Clinical Trial. J. Periodontol. 2004, 75, 1668–1677. [Google Scholar] [CrossRef]
  9. Rexhepi, I.; Paolantonio, M.; Romano, L.; Serroni, M.; Santamaria, P.; Secondi, L.; Paolantonio, G.; Sinjari, B.; De Ninis, P.; Femminella, B. Efficacy of Inorganic Bovine Bone Combined with Leukocyte and Platelet-Rich Fibrin or Collagen Membranes for Treating Unfavorable Periodontal Infrabony Defects: Randomized Non-Inferiority Trial. J. Periodontol. 2021, 92, 1576–1587. [Google Scholar] [CrossRef]
  10. Windisch, P.; Sculean, A.; Gera, I. GTR with Three Different Types of Membranes in the Treatment of Intrabony Periodontal Defects: Three-Year Results in Sixty Consecutive Cases. J. Long Term Eff. Med. Implant. 1999, 9, 235–246. [Google Scholar]
  11. Sculean, A.; Windisch, P.; Chiantella, G.C.; Donos, N.; Brecx, M.; Reich, E. Treatment of Intrabony Defects with Enamel Matrix Proteins and Guided Tissue Regeneration. A Prospective Controlled Clinical Study. J. Clin. Periodontol. 2001, 28, 397–403. [Google Scholar] [CrossRef] [PubMed]
  12. Nayak, R.; Panda, S.; Mohanty, R.; Satpathy, A. Minced Platelet Rich Fibrin with Hydroxyapatite in Surgical Treatment of Apico-Marginal Periodontal Defects. Utkal Univ. J. Dent. Sci. 2015, 2, 54–59. [Google Scholar]
  13. Panda, S.; Purkayastha, A.; Mohanty, R.; Nayak, R.; Satpathy, A.; Das, A.C.; Kumar, M.; Mohanty, G.; Panda, S.; Fabbro, M.D. Plasma Rich in Growth Factors (PRGF) in Non-Surgical Periodontal Therapy: A Randomized Clinical Trial. Braz. Oral Res. 2020, 34, e034. [Google Scholar] [CrossRef]
  14. Sukumar, S.; Drízhal, I.; Paulusová, V.; Bukac, J. Surgical Treatment of Periodontal Intrabony Defects with Calcium Sulphate in Combination with Beta-Tricalcium Phosphate: Clinical Observations Two Years Post-Surgery. Acta Medica. 2011, 54, 13–20. [Google Scholar] [CrossRef] [PubMed]
  15. Babrawala, I.; Munivenkatappa Lakshmaiah Venkatesh, P.; Bangalore Varadhan, K. A Novel Approach Using 15% Natural Chitosan Gel 
in the Management of Intrabony Defects: A Pilot Study. Chin. J. Dent. Res. 2016, 19, 231–237. [Google Scholar] [CrossRef] [PubMed]
  16. IJMS|Free Full-Text|Smart Hydrogels for Advanced Drug Delivery Systems. Available online: https://www.mdpi.com/1422-0067/23/7/3665 (accessed on 14 July 2023).
  17. Panda, S.; Doraiswamy, J.; Malaiappan, S.; Varghese, S.S.; Del Fabbro, M. Additive Effect of Autologous Platelet Concentrates in Treatment of Intrabony Defects: A Systematic Review and Meta-Analysis. J. Investig. Clin. Dent. 2016, 7, 13–26. [Google Scholar] [CrossRef] [PubMed]
  18. Panda, S.; Sankari, M.; Satpathy, A.; Jayakumar, D.; Mozzati, M.; Mortellaro, C.; Gallesio, G.; Taschieri, S.; Del Fabbro, M. Adjunctive Effect of Autologus Platelet-Rich Fibrin to Barrier Membrane in the Treatment of Periodontal Intrabony Defects. J. Craniofacial Surg. 2016, 27, 691–696. [Google Scholar] [CrossRef]
  19. Serroni, M.; Paolantonio, M.; Romano, L.; Santamaria, P.; Rexhepi, I.; Sinjari, B.; Paolantonio, G.; Secondi, L.; De Ninis, P.; Femminella, B. Added Benefit of L-PRF to Autogenous Bone Grafts in the Treatment of Degree II Furcation Involvement in Mandibular Molars. J. Periodontol. 2022, 93, 1486–1499. [Google Scholar] [CrossRef]
  20. Goodson, J.M.; Haffajee, A.; Socransky, S.S. Periodontal Therapy by Local Delivery of Tetracycline. J. Clin. Periodontol. 1979, 6, 83–92. [Google Scholar] [CrossRef]
  21. Rajeshwari, H.R.; Dhamecha, D.; Jagwani, S.; Rao, M.; Jadhav, K.; Shaikh, S.; Puzhankara, L.; Jalalpure, S. Local Drug Delivery Systems in the Management of Periodontitis: A Scientific Review. J. Control. Release 2019, 307, 393–409. [Google Scholar] [CrossRef]
  22. Addy, M.; Martin, M. Systemic Antimicrobials in the Treatment of Chronic Periodontal Diseases: A Dilemma. Oral Dis. 2003, 9, 38–44. [Google Scholar] [CrossRef]
  23. Coutinho, A. Honeybee Propolis Extract in Periodontal Treatment: A Clinical and Microbiological Study of Propolis in Periodontal Treatment. Indian J. Dent. Res. 2012, 23, 294. [Google Scholar] [CrossRef] [PubMed]
  24. Dolci, P.; OZINO, O. Study of the in vitro Sensitivity to Honey Bee Propolis of Staphylococcus Aureus Strains Characterized by Different Sensitivity to Antibiotics. Ann. Microbiol. 2003, 53. [Google Scholar]
  25. Pasupuleti, V.R.; Sammugam, L.; Ramesh, N.; Gan, S.H. Honey, Propolis, and Royal Jelly: A Comprehensive Review of Their Biological Actions and Health Benefits. Oxid. Med. Cell Longev. 2017, 2017, 1259510. [Google Scholar] [CrossRef] [PubMed]
  26. Przybyłek, I.; Karpiński, T.M. Antibacterial Properties of Propolis. Molecules 2019, 24, 2047. [Google Scholar] [CrossRef]
  27. Martinello, M.; Mutinelli, F. Antioxidant Activity in Bee Products: A Review. Antioxidants 2021, 10, 71. [Google Scholar] [CrossRef]
  28. Nakao, R.; Senpuku, H.; Ohnishi, M.; Takai, H.; Ogata, Y. Effect of Topical Administration of Propolis in Chronic Periodontitis. Odontology 2020, 108, 704–714. [Google Scholar] [CrossRef]
  29. Sparabombe, S.; Monterubbianesi, R.; Tosco, V.; Orilisi, G.; Hosein, A.; Ferrante, L.; Putignano, A.; Orsini, G. Efficacy of an All-Natural Polyherbal Mouthwash in Patients with Periodontitis: A Single-Blind Randomized Controlled Trial. Front. Physiol. 2019, 10, 632. [Google Scholar] [CrossRef]
  30. Giammarinaro, E.; Marconcini, S.; Genovesi, A.; Poli, G.; Lorenzi, C.; Covani, U. Propolis as an Adjuvant to Non-Surgical Periodontal Treatment: A Clinical Study with Salivary Anti-Oxidant Capacity Assessment. Minerva Stomatol. 2018, 67, 183–188. [Google Scholar] [CrossRef]
  31. Piekarz, T.; Mertas, A.; Wiatrak, K.; Rój, R.; Kownacki, P.; Śmieszek-Wilczewska, J.; Kopczyńska, E.; Wrzoł, M.; Cisowska, M.; Szliszka, E.; et al. The Influence of Toothpaste Containing Australian Melaleuca Alternifolia Oil and Ethanolic Extract of Polish Propolis on Oral Hygiene and Microbiome in Patients Requiring Conservative Procedures. Molecules 2017, 22, 1957. [Google Scholar] [CrossRef]
  32. Anauate-Netto, C.; Anido-Anido, A.; Leegoy, H.R.; Matsumoto, R.; Alonso, R.C.B.; Marcucci, M.C.; Paulino, N.; Bretz, W.A. Randomized, Double-Blind, Placebo-Controlled Clinical Trial on the Effects of Propolis and Chlorhexidine Mouthrinses on Gingivitis. Braz. Dent. Sci. 2014, 17, 11–15. [Google Scholar] [CrossRef] [PubMed]
  33. Mohsin, S.; Manohar, B.; Rajesh, S.; Asif, Y. The Effects of a Dentifrice Containing Propolis on Mutans Streptococci: A Clinico-Microbiological Study. Ethiop. J. Health Sci. 2015, 25, 9–16. [Google Scholar] [CrossRef] [PubMed]
  34. Tanasiewicz, M.; Skucha-Nowak, M.; Dawiec, M.; Król, W.; Skaba, D.; Twardawa, H. Influence of Hygienic Preparations with a 3% Content of Ethanol Extract of Brazilian Propolis on the State of the Oral Cavity. Adv. Clin. Exp. Med. 2012, 21, 81–92. [Google Scholar] [PubMed]
  35. Pereira, E.M.R.; da Silva, J.L.D.C.; Silva, F.F.; De Luca, M.P.; Ferreira, E.F.E.; Lorentz, T.C.M.; Santos, V.R. Clinical Evidence of the Efficacy of a Mouthwash Containing Propolis for the Control of Plaque and Gingivitis: A Phase II Study. Evid. Based Complement Altern. Med. 2011, 2011, 750249. [Google Scholar] [CrossRef] [PubMed]
  36. de Carvalho Furtado Júnior, J.H.; Valadas, L.A.R.; da Cruz Fonseca, S.G.; Lobo, P.L.D.; Calixto, L.H.M.; Lima, A.G.F.; de Aguiar, M.H.R.; Arruda, I.S.; Lotif, M.A.L.; Rodrigues Neto, E.M.; et al. Clinical and Microbiological Evaluation of Brazilian Red Propolis Containing-Dentifrice in Orthodontic Patients: A Randomized Clinical Trial. Evid.-Based Complement. Altern. Med. 2020, 2020, e8532701. [Google Scholar] [CrossRef]
  37. Shabbir, A.; Rashid, M.; Tipu, H.N.; Shabbir, A.; Rashid, M.; Tipu, H.N. Propolis, A Hope for the Future in Treating Resistant Periodontal Pathogens. Cureus 2016, 8, 682. [Google Scholar] [CrossRef]
  38. Skaba, D.; Morawiec, T.; Tanasiewicz, M.; Mertas, A.; Bobela, E.; Szliszka, E.; Skucha-Nowak, M.; Dawiec, M.; Yamamoto, R.; Ishiai, S.; et al. Influence of the Toothpaste with Brazilian Ethanol Extract Propolis on the Oral Cavity Health. Evid. Based Complement Altern. Med. 2013, 2013, 215391. [Google Scholar] [CrossRef]
  39. Niedzielska, I.; Puszczewicz, Z.; Mertas, A.; Niedzielski, D.; Różanowski, B.; Baron, S.; Konopka, T.; Machorowska-Pieniążek, A.; Skucha-Nowak, M.; Tanasiewicz, M.; et al. The Influence of Ethanolic Extract of Brazilian Green Propolis Gel on Hygiene and Oral Microbiota in Patients after Mandible Fractures. Biomed. Res. Int. 2016, 2016, 9190814. [Google Scholar] [CrossRef]
  40. Morawiec, T.; Dziedzic, A.; Niedzielska, I.; Mertas, A.; Tanasiewicz, M.; Skaba, D.; Kasperski, J.; Machorowska-Pieniążek, A.; Kucharzewski, M.; Szaniawska, K.; et al. The Biological Activity of Propolis-Containing Toothpaste on Oral Health Environment in Patients Who Underwent Implant-Supported Prosthodontic Rehabilitation. Evid. Based Complement Altern. Med. 2013, 2013, 704947. [Google Scholar] [CrossRef]
  41. Machorowska-Pieniążek, A.; Morawiec, T.; Mertas, A.; Tanasiewicz, M.; Dziedzic, A.; Król, W. Influence of Propolis on Hygiene, Gingival Condition, and Oral Microflora in Patients with Cleft Lip and Palate Treated with Fixed Orthodontic Appliances. Evid. Based Complement Altern. Med. 2013, 2013, 183915. [Google Scholar] [CrossRef]
  42. Sanghani, N.N.; Bm, S.; Savita, S. Health from the Hive: Propolis as an Adjuvant in the Treatment of Chronic Periodontitis—A Clinicomicrobiologic Study. J. Clin. Diagn. Res. 2014, 8, ZC41–ZC44. [Google Scholar] [CrossRef] [PubMed]
  43. Chandrasekaran, K.; Nalini, S.; Paul, P.; Parveen, A. 18-Evaluation of Clinical Efficacy of Subgingivally Delivered Propolis. Int. J. Sci. Res. 2018, 7, 757–760. [Google Scholar]
  44. Caton, J.G.; Armitage, G.; Berglundh, T.; Chapple, I.L.C.; Jepsen, S.; Kornman, K.S.; Mealey, B.L.; Papapanou, P.N.; Sanz, M.; Tonetti, M.S. A New Classification Scheme for Periodontal and Peri-Implant Diseases and Conditions—Introduction and Key Changes from the 1999 Classification. J. Clin. Periodontol. 2018, 45 (Suppl. S20), S1–S8. [Google Scholar] [CrossRef]
  45. Papapanou, P.N.; Sanz, M.; Buduneli, N.; Dietrich, T.; Feres, M.; Fine, D.H.; Flemmig, T.F.; Garcia, R.; Giannobile, W.V.; Graziani, F.; et al. Periodontitis: Consensus Report of Workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J. Periodontol. 2018, 89, S173–S182. [Google Scholar] [CrossRef]
  46. The Gingival Index, the Plaque Index and the Retention Index Systems—PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/5237684/ (accessed on 6 July 2023).
  47. Loe, H.; Silness, J. Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol. Scand. 1963, 21, 533–551. [Google Scholar] [CrossRef]
  48. Mühlemann, H.R.; Son, S. Gingival Sulcus Bleeding—A Leading Symptom in Initial Gingivitis. Helv. Odontol. Acta 1971, 15, 107–113. [Google Scholar]
  49. Park, Y.K.; Alencar, S.M.; Aguiar, C.L. Botanical Origin and Chemical Composition of Brazilian Propolis. J. Agric. Food Chem. 2002, 50, 2502–2506. [Google Scholar] [CrossRef]
  50. Wagh, V.D. Propolis: A Wonder Bees Product and Its Pharmacological Potentials. Adv. Pharmacol. Sci. 2013, 2013, 308249. [Google Scholar] [CrossRef] [PubMed]
  51. Maksimova-Todorova, V.; Manolova, N.; Gegova, G.; Serkedzhieva, I.; Uzunov, S. Antiviral action of fractions isolated from propolis. Acta Microbiol. Bulg. 1985, 17, 79–85. [Google Scholar] [PubMed]
  52. Kujumgiev, A.; Tsvetkova, I.; Serkedjieva, Y.; Bankova, V.; Christov, R.; Popov, S. Antibacterial, Antifungal and Antiviral Activity of Propolis of Different Geographic Origin. J. Ethnopharmacol. 1999, 64, 235–240. [Google Scholar] [CrossRef] [PubMed]
  53. Mirzoeva, O.K.; Calder, P.C. The Effect of Propolis and Its Components on Eicosanoid Production during the Inflammatory Response. Prostaglandins Leukot. Essent. Fat. Acids 1996, 55, 441–449. [Google Scholar] [CrossRef] [PubMed]
  54. Greenaway, W.; Scaysbrook, T.; Whatley, F.R. Composition of Propolis in Oxfordshire, U.K. and Its Relation to Poplar Bud Exudate. Z. Für Naturforschung C 1988, 43, 301–304. [Google Scholar] [CrossRef]
  55. Marcucci, M.C. Propolis: Chemical Composition, Biological Properties and Therapeutic Activity. Apidologie 1995, 26, 83–99. [Google Scholar] [CrossRef]
  56. Krol, W.; Scheller, S.; Czuba, Z.; Matsuno, T.; Zydowicz, G.; Shani, J.; Mos, M. Inhibition of Neutrophils’ Chemiluminescence by Ethanol Extract of Propolis (EEP) and Its Phenolic Components. J. Ethnopharmacol. 1996, 55, 19–25. [Google Scholar] [CrossRef] [PubMed]
  57. Burdock, G.A. Review of the Biological Properties and Toxicity of Bee Propolis (Propolis). Food Chem. Toxicol. 1998, 36, 347–363. [Google Scholar] [CrossRef]
  58. Panda, S.; Sankari, M.; Jayakumar, N.D.; Varghese, S. Additive Effect of Platelet Rich Fibrin in Treatment of Intrabony Defects-A Systematic Review and Meta-Analysis. JPR Bio. Med. Rx An. Int. J. 2013, 1, 700–706. [Google Scholar]
  59. Del Fabbro, M.; Karanxha, L.; Panda, S.; Bucchi, C.; Doraiswamy, J.N.; Sankari, M.; Ramamoorthi, S.; Varghese, S.; Taschieri, S. Autologous Platelet Concentrates for Treating Periodontal Infrabony Defects. Cochrane Database Syst. Rev. 2018. [Google Scholar] [CrossRef]
  60. Del Fabbro, M.; Panda, S.; Jayakumar, N.D.; Sankari, M.; Varghese, S.; Ramamoorthi, S.; Ceci, C.; Ceresoli, V.; Taschieri, S. Autologous Platelet Concentrates for Treatment of Periodontal Defects. Cochrane Database Syst. Rev. 2014. [Google Scholar] [CrossRef]
  61. Panda, S.; Ramamoorthi, S.; Jayakumar, N.D.; Sankari, M.; Varghese, S.S. Platelet Rich Fibrin and Alloplast in the Treatment of Intrabony Defect. J. Pharm. Bioallied Sci. 2014, 6, 127. [Google Scholar] [CrossRef]
  62. Panda, S.; Jayakumar, N.D.; Sankari, M.; Varghese, S.S.; Kumar, D.S. Platelet Rich Fibrin and Xenograft in Treatment of Intrabony Defect. Contemp. Clin. Dent. 2014, 5, 550. [Google Scholar] [CrossRef]
  63. Chatterjee, S.S.; Das, A.C.; Panda, S. Platelet Rich Fibrin: A Promising Innovation in Periodontics. Indian J. Public Health Res. Dev. 2019, 10, 772–775. [Google Scholar] [CrossRef]
  64. Das, S.; Mohanty, R.; Satpathy, A.; Nayak, R.; Panda, S. Newer Advances in Non-Surgical Periodontal Therapy: An Update. Indian J. Public Health Res. Dev. 2019, 10, e095. [Google Scholar] [CrossRef]
  65. Del Fabbro, M.; Lolato, A.; Panda, S.; Corbella, S.; Satpathy, A.; Das, A.C.; Kumar, M.; Taschieri, S. Methodological Quality Assessment of Systematic Reviews on Autologous Platelet Concentrates for the Treatment of Periodontal Defects. J. Evid. Based Dent. Pract. 2017, 17, 239–255. [Google Scholar] [CrossRef]
  66. Mishra, S.; Misra, S.R.; Panda, S.; Mohanty, N.; Manfredi, B.; Parrini, M.; Giacomello, M.S.; Mortellaro, C.; Lucchina, A.G.; Annunziata, M. Role of Probiotics in Adjunct to Non-Surgical Periodontal Therapy in Patients with Chronic Periodontitis: A Systematic Review and Meta-Analysis. J. Biol. Regul. Homeost. Agents 2021, 35, 67–78. [Google Scholar]
  67. Beyene, D.H.; Shashamo, B.B.; Digesa, L.E.; Tariku, E.Z. Oral Hygiene Practices and Associated Factors among Patients Visiting Private Dental Clinics at Hawassa City, Southern Ethiopia, 2018. Int. J. Dent. 2021, 2021, 8868308. [Google Scholar] [CrossRef] [PubMed]
  68. Hunter, K.D.; Wilson, W.S. The Effects of Antidepressant Drugs on Salivary Flow and Content of Sodium and Potassium Ions in Human Parotid Saliva. Arch. Oral. Biol. 1995, 40, 983–989. [Google Scholar] [CrossRef] [PubMed]
  69. Tan, E.; Lexomboon, D.; Sandborgh-Englund, G.; Haasum, Y.; Johnell, K. Medications That Cause Dry Mouth As an Adverse Effect in Older People: A Systematic Review and Metaanalysis. J. Am. Geriatr. Soc. 2017, 66, 15151. [Google Scholar] [CrossRef] [PubMed]
  70. Bharti, V.; Bansal, C. Drug-Induced Gingival Overgrowth: The Nemesis of Gingiva Unravelled. J. Indian Soc. Periodontol. 2013, 17, 182–187. [Google Scholar] [CrossRef]
  71. Priyanka, K.; Sudhir, K.M.; Reddy, V.C.S.; Kumar, R.V.S.; Srinivasulu, G. Impact of Alcohol Dependency on Oral Health—A Cross-Sectional Comparative Study. J. Clin. Diagn Res. 2017, 11, ZC43–ZC46. [Google Scholar] [CrossRef]
  72. Bhandari, A.; Bhatta, N. Tobacco and Its Relationship with Oral Health. J. Nepal. Med. Assoc. 2021, 59, 1204–1206. [Google Scholar] [CrossRef]
  73. Barnes, E. The Importance of Nutrition in Oral Health in the General Population and Among Children and Adolescents. Honor. Theses Univ. Neb.-Linc. 2022. [Google Scholar]
  74. Mörmann, J.E.; Mühlemann, H.R. Oral Starch Degradation and Its Influence on Acid Production in Human Dental Plaque. Caries Res. 1981, 15, 166–175. [Google Scholar] [CrossRef] [PubMed]
  75. Signoretto, C.; Bianchi, F.; Burlacchini, G.; Sivieri, F.; Spratt, D.; Canepari, P. Drinking Habits Are Associated with Changes in the Dental Plaque Microbial Community. J. Clin. Microbiol. 2010, 48, 347–356. [Google Scholar] [CrossRef] [PubMed]
  76. Lingström, P.; Birkhed, D.; Granfeldt, Y.; Björck, I. pH Measurements of Human Dental Plaque after Consumption of Starchy Foods Using the Microtouch and the Sampling Method. Caries Res. 1993, 27, 394–401. [Google Scholar] [CrossRef]
  77. Lingström, P.; Holm, J.; Birkhed, D.; Björck, I. Effects of Variously Processed Starch on pH of Human Dental Plaque. Scand J. Dent. Res. 1989, 97, 392–400. [Google Scholar] [CrossRef]
  78. Schachtele, C.F.; Jensen, M.E. Comparison of Methods for Monitoring Changes in the pH of Human Dental Plaque. J. Dent. Res. 1982, 61, 1117–1125. [Google Scholar] [CrossRef]
  79. Lingström, P.; Imfeld, T.; Birkhed, D. Comparison of Three Different Methods for Measurement of Plaque-pH in Humans after Consumption of Soft Bread and Potato Chips. J. Dent. Res. 1993, 72, 865–870. [Google Scholar] [CrossRef]
  80. Rugg-Gunn, A.J.; Edgar, W.M.; Jenkins, G.N. The Effect of Altering the Position of a Sugary Food in a Meal upon Plaque pH in Human Subjects. J. Dent. Res. 1981, 60, 867–872. [Google Scholar] [CrossRef]
  81. Mundorff-Shrestha, S.A.; Featherstone, J.D.; Eisenberg, A.D.; Cowles, E.; Curzon, M.E.; Espeland, M.A.; Shields, C.P. Cariogenic Potential of Foods. II. Relationship of Food Composition, Plaque Microbial Counts, and Salivary Parameters to Caries in the Rat Model. Caries Res. 1994, 28, 106–115. [Google Scholar] [CrossRef]
  82. Vasiliou, A.; Shankardass, K.; Nisenbaum, R.; Quiñonez, C. Current Stress and Poor Oral Health. BMC Oral. Health 2016, 16, 88. [Google Scholar] [CrossRef]
  83. Marcenes, W.S.; Sheiham, A. The Relationship between Work Stress and Oral Health Status. Soc. Sci. Med. 1992, 35, 1511–1520. [Google Scholar] [CrossRef] [PubMed]
  84. Deinzer, R.; Granrath, N.; Spahl, M.; Linz, S.; Waschul, B.; Herforth, A. Stress, Oral Health Behaviour and Clinical Outcome. Br. J. Health Psychol. 2005, 10, 269–283. [Google Scholar] [CrossRef] [PubMed]
  85. Armfield, J.M.; Mejía, G.C.; Jamieson, L.M. Socioeconomic and Psychosocial Correlates of Oral Health. Int. Dent. J. 2013, 63, 202–209. [Google Scholar] [CrossRef] [PubMed]
  86. Kisely, S.; Baghaie, H.; Lalloo, R.; Siskind, D.; Johnson, N.W. A Systematic Review and Meta-Analysis of the Association between Poor Oral Health and Severe Mental Illness. Psychosom. Med. 2015, 77, 83–92. [Google Scholar] [CrossRef]
  87. Vettore, M.V.; Leão, A.T.T.; Monteiro Da Silva, A.M.; Quintanilha, R.S.; Lamarca, G.A. The Relationship of Stress and Anxiety with Chronic Periodontitis. J. Clin. Periodontol. 2003, 30, 394–402. [Google Scholar] [CrossRef]
  88. Solis, A.C.O.; Lotufo, R.F.M.; Pannuti, C.M.; Brunheiro, E.C.; Marques, A.H.; Lotufo-Neto, F. Association of Periodontal Disease to Anxiety and Depression Symptoms, and Psychosocial Stress Factors. J. Clin. Periodontol. 2004, 31, 633–638. [Google Scholar] [CrossRef]
  89. Aimetti, M.; Romano, F.; Torta, I.; Cirillo, D.; Caposio, P.; Romagnoli, R. Debridement and Local Application of Tetracycline-Loaded Fibres in the Management of Persistent Periodontitis: Results after 12 Months. J. Clin. Periodontol. 2004, 31, 166–172. [Google Scholar] [CrossRef]
  90. Ghisalberti, E.L. Propolis: A Review. Bee World 1979, 60, 59–84. [Google Scholar] [CrossRef]
  91. Ferreira, S.; Dias, B.; Obregón, C.; Gomes, C.; Pereira, R.; Godoy, J.; Svidzinski, T.; Bruschi, M. Microparticles Containing Propolis and Metronidazole: In Vitro Characterization, Release Study and Antimicrobial Activity against Periodontal Pathogens. Pharm. Dev. Technol. 2013, 19, 173–180. [Google Scholar] [CrossRef]
  92. Bruschi, M.L.; Lara, E.H.G.; Martins, C.H.G.; Vinholis, A.H.C.; Casemiro, L.A.; Panzeri, H.; Gremião, M.P.D. Preparation and Antimicrobial Activityof Gelatin Microparticles Containing Propolis Against Oral Pathogens. Drug Dev. Ind. Pharm. 2006, 32, 229–238. [Google Scholar] [CrossRef]
  93. Oda, H.; Nakagawa, T.; Maruyama, K.; Dono, Y.; Katsuragi, H.; Sato, S. Effect of Brazilian Green Propolis on Oral Pathogens and Human Periodontal Fibroblasts. J. Oral Biosci. 2016, 58, 50–54. [Google Scholar] [CrossRef]
  94. Shi, B.; Zhao, Y.; Yuan, X. Effects of MTA and Brazilian Propolis on the Biological Properties of Dental Pulp Cells. Braz. Oral. Res. 2020, 33, e117. [Google Scholar] [CrossRef]
  95. Al-Shaher, A.; Wallace, J.; Agarwal, S.; Bretz, W.; Baugh, D. Effect of Propolis on Human Fibroblasts from the Pulp and Periodontal Ligament. J. Endod. 2004, 30, 359–361. [Google Scholar] [CrossRef] [PubMed]
  96. Comparative Evaluation of Locally Delivered Probiotic Paste and Chlorhexidine Gel as an Adjunct to Scaling and Root Planing in Treating Chronic Periodontitis: A Split-Mouth Randomized Clinical Trial—PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/35602526/ (accessed on 17 October 2023).
  97. Grover, V.; Kapoor, A.; Malhotra, R.; Battu, V.S.; Bhatia, A.; Sachdeva, S. To Assess the Effectiveness of a Chlorhexidine Chip in the Treatment of Chronic Periodontitis: A Clinical and Radiographic Study. J. Indian Soc. Periodontol. 2011, 15, 139–146. [Google Scholar] [CrossRef] [PubMed]
  98. Taalab, M.R.; Mahmoud, S.A.; Moslemany, R.M.E.; Abdelaziz, D.M. Intrapocket Application of Tea Tree Oil Gel in the Treatment of Stage 2 Periodontitis. BMC Oral. Health 2021, 21, 239. [Google Scholar] [CrossRef]
  99. Binnie, W.H.; Forrest, J.O. A Study of Tissue Response to Cyanoacrylate Adhesive in Periodontal Surgery. J. Periodontol. 1974, 45, 619–625. [Google Scholar] [CrossRef]
  100. Jain, R.; Wairkar, S. Recent Developments and Clinical Applications of Surgical Glues: An Overview. Int. J. Biol. Macromol. 2019, 137, 95–106. [Google Scholar] [CrossRef]
  101. Sagar, P.; Prasad, K.; Lalitha, R.M.; Ranganath, K. Cyanoacrylate for Intraoral Wound Closure: A Possibility? Int. J. Biomater. 2015, 2015, 165428. [Google Scholar] [CrossRef]
  102. Borie, E.; Rosas, E.; Kuramochi, G.; Etcheberry, S.; Olate, S.; Weber, B. Oral Applications of Cyanoacrylate Adhesives: A Literature Review. Biomed Res. Int. 2019, 2019, 8217602. [Google Scholar] [CrossRef]
  103. Kumar, R.; Sharma, G. Therapeutic Evaluation of Local Drug Delivery System Containing 1.5% Chlorhexidine Used as an Adjunct to Scaling and Root Planing for the Treatment of Chronic Periodontitis—A Clinical and Microbiologcal Study. IP Int. J. Periodontol. Implantol. 2019, 4, 103–106. [Google Scholar] [CrossRef]
  104. Basavaiah, N.D.; Suryakanth, D.B. Propolis and Allergic Reactions. J. Pharm. Bioallied. Sci. 2012, 4, 345. [Google Scholar] [CrossRef]
Biomolecules 13 01576 g001
Figure 1. Characterization of propolis nanoparticles using FE-SEM, mag. 20,000×; (i) flower-shaped nano-particle, mag. 50,000×.
Figure 1. Characterization of propolis nanoparticles using FE-SEM, mag. 20,000×; (i) flower-shaped nano-particle, mag. 50,000×.
Biomolecules 13 01576 g001
Biomolecules 13 01576 g002
Figure 2. CONSORT flow chart showing allocation of sites.
Figure 2. CONSORT flow chart showing allocation of sites.
Biomolecules 13 01576 g002
Table 1. Distribution of sites in test and control group.
Table 1. Distribution of sites in test and control group.
TeethGroupTotal
A: SRP + PRO 1B: SRP + SALINE 2
Incisor4711
Canine437
Premolar347
Molar9615
Total202040
1 SRP + PRO = scaling and root planing followed by Propolis delivery; 2 SRP + SALINE = scaling and root planing followed by saline delivery.
Table 2. Distribution of age in test and control group.
Table 2. Distribution of age in test and control group.
Treatment GroupNo. of PatientMeanStandard DeviationMean Standard Error
SRP + PRO2049.9011.6252.599
SRP + Saline2050.1012.2082.730
Table 3. Intergroup comparison of PI and GI at different time intervals in both groups.
Table 3. Intergroup comparison of PI and GI at different time intervals in both groups.
ParameterGroupsNMedianMax.Min.Average RankSum of Ranksp-Value
PI_BaselineSRP + PRO201.60002.00001.250021.50430.000.602
SRP + Saline201.55001.62501.250019.50390.00
Total40
PI_1monthsSRP + PRO200.56251.00000.250019.03380.500.429
SRP + Saline200.63750.75000.250021.98439.50
Total40
PI_3monthsSRP + PRO200.67501.25000.250016.88337.500.429
SRP + Saline200.88751.00000.500024.13482.50
Total40
GI_baselineSRP + PRO201.75002.00001.500020.50410.001.000
SRP + Saline201.75001.75001.500020.50410.00
Total40
GI_1monthsSRP + PRO200.72501.25000.500013.40268.00* 0.000
SRP + Saline201.03751.00000.500027.60552.00
Total40
GI_3monthsSRP + PRO200.32501.00000.250014.40288.00* 0.001
SRP + Saline200.56250.50000.250026.60532.00
Total40
* Mann-Whitney U Test p < 0.05 statistically significant.
Table 4. Intergroup comparison of BOP, PPD, and RAL at different time intervals in both groups.
Table 4. Intergroup comparison of BOP, PPD, and RAL at different time intervals in both groups.
ParameterGroupsNMedianMax.Min.Average RankSum of Ranksp-Value
BOP_BaselineSRP + PRO202.46253.00002.000021.18423.500.718
SRP + Saline202.42502.50002.000019.83396.50
Total40
BOP_1monthsSRP + PRO200.43750.50000.000020.95305.700.718
SRP + Saline200.58750.50000.000018.93408.50
Total40
BOP_3monthsSRP + PRO200.16250.25000.000012.95259.00* 0.000
SRP + Saline200.45000.25000.000028.05561.00
Total40
PPD_baselineSRP + PRO204.90006.65004.000020.50410.001.000
SRP + Saline204.90006.00004.000020.50410.00
Total40
PPD_1monthsSRP + PRO202.90004.65002.000017.65353.000.127
SRP + Saline203.30005.00003.000023.35467.00
Total40
PPD_3monthsSRP + PRO202.45003.20002.000014.33286.50* 0.001
SRP + Saline203.15003.00002.000026.68533.50
Total40
RAL_BaselineSRP + PRO209.650011.30008.950021.08421.500.758
SRP + Saline209.550011.55008.000019.93398.50
Total40
RAL_1monthsSRP + PRO207.65006.55009.950019.10382.000.451
SRP + Saline207.950010.00006.000021.90438.00
Total40
RAL_3monthsSRP + PRO207.20009.95006.750016.90338.00* 0.05
SRP + Saline207.80009.00006.000024.10482.00
Total40
* Mann–Whitney U Test p < 0.05 statistically significant.
Table 5. Change in parameters at different time intervals in both groups.
Table 5. Change in parameters at different time intervals in both groups.
ParameterGroupsNMedianMax.Min.Average RankSum of Ranksp-Value
ChangePI_1monthSRP + PRO20−1.0375−0.25−1.5018.35367.000.253
SRP + Saline20−0.9125−0.25−1.5022.65453.00
Total40
ChangePI_3monthSRP + PRO20−0.9250−0.25−1.5016.30326.00* 0.023
SRP + Saline20−0.6625−0.00−1.2024.70494.00
Total40
ChangeGI_1monthSRP + PRO20−1.0250−0.50−1.2514.68293.50* 0.001
SRP + Saline20−0.7125−0.25−1.2526.33526.50
Total40
ChangeGI_3monthSRP + PRO20−1.4250−1.00−1.7515.40308.00* 0.005
SRP + Saline20−1.25−1.00−1.525.60512.00
Total40
ChangeBOP_1monthSRP + PRO20−2.0250−1.75−2.2514.35287.00* 0.001
SRP + Saline20−1.8375−1.75−2.2526.65533.00
Total40
ChangeBOP_3monthSRP + PRO20−2.3000−2.00−2.7513.75275.00* 0.000
SRP + Saline20−1.9750−1.75−2.2527.25545.00
Total40
ChangePPD_1monthSRP + PRO20−2.0000−1.00−3.0016.90338.00* 0.052
SRP + Saline20−1.6000−1.00−3.0024.10482.00
Total40
ChangePPD_3monthSRP + PRO20−2.4500−1.00−4.0015.48309.50* 0.006
SRP + Saline20−1.7500−1.00−3.0025.53510.50
Total40
ChangeRAL_1monthSRP + PRO20−2.7500−1.00−4.0016.90338.00* 0.052
SRP + Saline20−1.7500−1.00−3.0024.10482.00
Total40
ChangeRAL_3monthSRP + PRO20 15.48309.50* 0.006
SRP + Saline20 25.53510.50
Total40
* Mann-Whitney U Test p < 0.05 statistically significant.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Sahu, S.A.; Panda, S.; Das, A.C.; Mishra, L.; Rath, S.; Sokolowski, K.; Kumar, M.; Mohanty, R.; Nayak, R.; Satpathy, A.; et al. Efficacy of Sub-Gingivally Delivered Propolis Nanoparticle in Non-Surgical Management of Periodontal Pocket: A Randomized Clinical Trial. Biomolecules 2023, 13, 1576. https://doi.org/10.3390/biom13111576

AMA Style

Sahu SA, Panda S, Das AC, Mishra L, Rath S, Sokolowski K, Kumar M, Mohanty R, Nayak R, Satpathy A, et al. Efficacy of Sub-Gingivally Delivered Propolis Nanoparticle in Non-Surgical Management of Periodontal Pocket: A Randomized Clinical Trial. Biomolecules. 2023; 13(11):1576. https://doi.org/10.3390/biom13111576

Chicago/Turabian Style

Sahu, Sushree Ambika, Saurav Panda, Abhaya Chandra Das, Lora Mishra, Satchidananda Rath, Krzysztof Sokolowski, Manoj Kumar, Rinkee Mohanty, Rashmita Nayak, Anurag Satpathy, and et al. 2023. "Efficacy of Sub-Gingivally Delivered Propolis Nanoparticle in Non-Surgical Management of Periodontal Pocket: A Randomized Clinical Trial" Biomolecules 13, no. 11: 1576. https://doi.org/10.3390/biom13111576

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop